Reviews/SGLT2 Inhibitors/SGLT2 inhibitor kidney benefit extends to CKD patients without diabetes
· SG-CK-02 · v2
Across the studies that directly enrolled people with kidney disease who do not have diabetes, the drug moved kidney measures in the same helpful direction every time. A large trial analysis showed dapagliflozin lowered protein in the urine in people without diabetes and behaved consistently whether or not patients had diabetes [2], a model of that trial projected slower progression toward kidney failure in the combined with-and-without-diabetes group [14], and benefit on serious kidney outcomes was seen in that population [5]. A small dedicated trial in nondiabetic patients [6] and a real-world group of nondiabetic patients [10] pointed the same way. The catch is that most of the nondiabetic-specific signal comes from indirect measures like urine protein rather than hard kidney failure, from one uncontrolled observational group, and from analyses of a single trial. Because the direction is unanimous but the strongest nondiabetic-specific endpoints are missing, the panel judged the claim well supported but short of settled.
In a prespecified DAPA-CKD analysis, dapagliflozin reduced urinary albumin in patients without type 2 diabetes by -14.8% (95% CI -22.9 to -5.9; p=0.0016) and the authors report similar effects on clinical outcomes with or without diabetes [2]. A time-to-event model of DAPA-CKD data states patients with or without type 2 diabetes had slower CKD progression and projects the time to kidney failure delayed by 6.6 years [14]. A MRA-subgroup analysis of the same with-or-without-diabetes CKD population shows a composite kidney and CV outcome hazard ratio of 0.60 (95% CI 0.50-0.72) in those not on MRAs [5]. A dedicated randomized crossover trial in 31 nondiabetic stage 4 CKD patients reduced proteinuria by 0.50 g/24h (P=0.026) over 6 weeks [6], and a real-world cohort of 354 nondiabetic CKD patients showed the eGFR slope improve from -5.6 to -1.7 mL/min/1.73m2 per year (p<0.001) after initiation [10]. The contested point: The division is over whether the nondiabetic-specific evidence reaches hard kidney outcomes or stops at surrogates. The direct nondiabetic trials report albuminuria and short-term GFR ([2], [6]) or an uncontrolled slope change [10], while the hard-outcome and progression results sit in DAPA-CKD analyses that enrolled a mixed with-and-without-diabetes population ([2], [5], [14]). The smaller nondiabetic albuminuria effect in [2] (-14.8% vs -35.1%, pinteraction<0.0001) further complicates a clean 'extends to' reading.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from SGLT2 Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The direct nondiabetic-specific evidence rests on surrogate endpoints: [2]'s primary measure is albuminuria and [6] reports only 6-week GFR and proteinuria changes, not hard kidney failure outcomes.
[6]'s significant GFR decrease at 6 weeks is the expected acute haemodynamic dip (the paper frames it as ameliorating glomerular hyperfiltration), not evidence of long-term nephroprotection; N=31 and 6-week crossover is severely underpowered for the claim.
Where it remains uncertain. Hard-outcome and progression support is concentrated in DAPA-CKD analyses ([2], [5], [14]) and the nondiabetic-specific endpoints are surrogate-heavy ([2], [6]) or uncontrolled [10], so independent hard-endpoint replication in a purely nondiabetic population is absent from the corpus.
Aleatory
The dedicated nondiabetic trial [6] has N=31 over 6 weeks, so its estimates carry wide random variation and cannot resolve long-term outcome risk.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows a significant albuminuria reduction in the nondiabetic subgroup, though smaller than in diabetics (surrogate endpoint).
“The similar effects of dapagliflozin on clinical outcomes in patients with or without type 2 diabetes, but different effects on UACR, suggest that part of the protective effect of dapagliflozin in patients with chronic kidney disease might be mediated through pathways unrelated to reduction in albuminuria.”
Panel auditInternal validity: high · scope of inference: Albuminuria response to dapagliflozin in CKD patients with UACR 200-5000 mg/g, non-diabetic subgroup.Key limitations: albuminuria is a surrogate, not a hard kidney outcome · smaller relative reduction in non-diabetics · exploratory endpoint
Hard kidney composite benefit within the DAPA-CKD CKD population, which enrolled patients with and without type 2 diabetes.
“The effect of dapagliflozin on the primary outcome was consistent in participants prescribed (hazard ratio [HR] 0.76, 95% CI 0.40-1.47) and not prescribed (HR 0.60, 95% CI 0.50-0.72, P -interaction = 0.59) MRAs.”
Panel auditInternal validity: high · scope of inference: Whether dapagliflozin's kidney benefit in CKD is modified by concomitant MRA use.Key limitations: not stratified by diabetes status · small MRA subgroup · wide confidence intervals in subgroup
Dedicated nondiabetic stage 4 CKD RCT showing proteinuria reduction; short-term surrogate endpoints only.
“At 6 weeks, dapagliflozin significantly decreased GFR by 1.88 ± 5.00 ml/min per 1.73 m2 ( P = 0.022) and proteinuria by 0.50 (-0.10 to 0.80) g/24 h ( P = 0.026) versus placebo.”
Panel auditInternal validity: medium · scope of inference: Short-term renal haemodynamic and proteinuria effects of dapagliflozin in nondiabetic stage 4 CKD with proteinuria.Key limitations: n=31 · 6-week surrogate endpoints, no hard outcomes · effects reversed on withdrawal
3 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Convergent primary evidence directly in nondiabetic CKD supports the claim, but surrogate-heavy endpoints and dapagliflozin/DAPA-CKD concentration keep it below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Dedicated nondiabetic hard-endpoint trial. The nondiabetic-specific case rests on surrogates ([2], [6]) and one uncontrolled cohort [10]; a hard kidney-failure outcome in nondiabetic CKD is absent. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized, placebo-controlled trial restricted to nondiabetic CKD powered for a composite of sustained eGFR decline, kidney failure and renal death over multi-year follow-up.
Open question: Does SGLT2 inhibition reduce hard kidney-failure outcomes in nondiabetic CKD patients, not just surrogate markers? Why it is still open: The corpus's nondiabetic-specific endpoints are albuminuria [2], 6-week GFR and proteinuria [6], or an uncontrolled slope [10]; no primary study reports a nondiabetic hard-endpoint hazard ratio.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 23 Oct 2026 · protocol v0.19